{"id":390770,"date":"2017-12-19T00:00:00","date_gmt":"2017-12-19T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0013-2017-biopharma-chronic-myeloid-leukemia-current-treatment-physician-insights-us-2017\/"},"modified":"2026-03-31T10:49:06","modified_gmt":"2026-03-31T10:49:06","slug":"cutron0013-2017-biopharma-chronic-myeloid-leukemia-current-treatment-physician-insights-us-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0013-2017-biopharma-chronic-myeloid-leukemia-current-treatment-physician-insights-us-2017\/","title":{"rendered":"Chronic Myeloid Leukemia | Current Treatment | Physician Insights | US | 2017"},"content":{"rendered":"<p>Chronic myeloid leukemia is a slow progressive tumor, characterized by different phases of disease (chronic, accelerated, and blast). Treatment of chronic myeloid leukemia is dominated by oral BCR-ABL tyrosine kinase inhibitors. Treatment options for newly diagnosed chronic phase disease are dominated by TKIs, including first-to-market Gleevec (Novartis), Sprycel (Bristol-Myers Squibb), and Tasigna (Novartis); treatment options for patients who are resistant or intolerant to prior therapy (and in patients with accelerated and\/or blast phase disease) include Bosulif (Pfizer), Iclusig (Ariad), and Synribo (Teva).<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>What percentage of drug-treated, newly diagnosed, chronic phase chronic myeloid leukemia patients are prescribed BCR-ABL tyrosine kinase inhibitors as first-line and second-line treatment by surveyed physicians?<\/li>\n<li>What are the key drivers and obstacles determining current prescribing patterns in the chronic myeloid leukemia treatment armamentarium?<\/li>\n<li>How the entry of generic Gleveec has affected the treatment preference of hematologists?<\/li>\n<li>What are surveyed physicians\u2019 perceptions of the intended duration of tyrosine kinase inhibitor treatment for chronic myeloid leukemia versus their actual clinical practice? To what extent are their patients compliant?<\/li>\n<\/ul>\n<p><strong><strong>Product Description:<\/strong><\/strong><\/p>\n<p><strong>Current Treatment:<\/strong> Provides physician insights on prescribing behavior, treatment paths, and the factors and perceptions driving brand usage so you can understand each brand\u2019s performance and improve or defend your competitive position.<\/p>\n","protected":false},"template":"","class_list":["post-390770","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-chronic-myeloid-leukemia","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390770","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390770\/revisions"}],"predecessor-version":[{"id":393894,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390770\/revisions\/393894"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390770"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}